Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABIOMED INCABMD · Entity 121309 | VP, Corporate Controller | February 28, 2018 | March 02, 2018 |
| Anika Therapeutics, Inc.ANIK · Entity 6005 | SVP, CAO & Treasurer | March 19, 2026 | March 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABIOMED INC
Report date February 28, 2018 · Filed March 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 par valueSEC Table I · non-derivative | Direct | 7,079 |
Reported balance
Holding disclosure · report date 2018-02-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,079 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.25 · Expires 2025-05-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-02-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 3, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F3: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 2 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.62 · Expires 2016-05-24 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-02-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 3, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 2 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $134.51 · Expires 2027-05-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-02-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 3, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 2 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 3, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
F2: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 3, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
F3: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 2
Anika Therapeutics, Inc.
Report date March 19, 2026 · Filed March 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 13,097 |
Reported balance
After 2026-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-19 · Grant · Acquired 13,097 · Balance 13,097 F1: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended (the "2017 Plan"), and the applicable award agreement. F2: Vests in three equal annual installments, with the first installment vesting on March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 11,194 |
Reported balance
After 2026-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-19 · Grant · Acquired 11,194 · Balance 11,194 F1: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended (the "2017 Plan"), and the applicable award agreement. F3: Vests fully on March 19, 2029, subject to the Reporting Person's continuous service to the Issuer as of such date. |
| Premium Priced Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $15.60 · Expires 2036-03-19 | Direct | 17,663 |
Reported balance
After 2026-03-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-19 · Grant · Acquired 17,663 · Balance 17,663 F4: Represents a Premium Priced Stock Appreciation Right ("PPSAR") granted under the 2017 Plan. The PPSAR exercise price per share is equal to 110% of the Fair Market Value (as defined in the 2017 Plan) of a share of common stock on the Grant Date. The PPSAR vests in three equal annual installments beginning March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. The PPSAR is payable in cash, shares of common stock, or a combination thereof, at the Issuer's discretion, in accordance with the 2017 Plan, as amended, and the applicable award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended (the "2017 Plan"), and the applicable award agreement.
F2: Vests in three equal annual installments, with the first installment vesting on March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3: Vests fully on March 19, 2029, subject to the Reporting Person's continuous service to the Issuer as of such date.
F4: Represents a Premium Priced Stock Appreciation Right ("PPSAR") granted under the 2017 Plan. The PPSAR exercise price per share is equal to 110% of the Fair Market Value (as defined in the 2017 Plan) of a share of common stock on the Grant Date. The PPSAR vests in three equal annual installments beginning March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. The PPSAR is payable in cash, shares of common stock, or a combination thereof, at the Issuer's discretion, in accordance with the 2017 Plan, as amended, and the applicable award agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2026 Filed Mar 23, 2026 21:23 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantPremium Priced Stock Appreciation Rights · Derivative | 17,663 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0001193125-26-120005 · ownership.xml · derivative · entry 3 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,663 Underlying: Common Stock · 17,663 shares Expires 2036-03-19 F4 · derivative.exercise_date: Represents a Premium Priced Stock Appreciation Right ("PPSAR") granted under the 2017 Plan. The PPSAR exercise price per share is equal to 110% of the Fair Market Value (as defined in the 2017 Plan) of a share of common stock on the Grant Date. The PPSAR vests in three equal annual installments beginning March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. The PPSAR is payable in cash, shares of common stock, or a combination thereof, at the Issuer's discretion, in accordance with the 2017 Plan, as amended, and the applicable award agreement. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 21:23 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 11,194 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-120005 · ownership.xml · derivative · entry 2 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,194 Underlying: Common Stock · 11,194 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended (the "2017 Plan"), and the applicable award agreement. F3 · derivative.exercise_date: Vests fully on March 19, 2029, subject to the Reporting Person's continuous service to the Issuer as of such date. F3 · derivative.expiration_date: Vests fully on March 19, 2029, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 21:23 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 13,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-120005 · ownership.xml · derivative · entry 1 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,097 Underlying: Common Stock · 13,097 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended (the "2017 Plan"), and the applicable award agreement. F2 · derivative.exercise_date: Vests in three equal annual installments, with the first installment vesting on March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.expiration_date: Vests in three equal annual installments, with the first installment vesting on March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:39 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 2,658 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111492 · ownership.xml · derivative · entry 7 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,659 Underlying: Common Stock · 2,658 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: On March 15, 2024, the Reporting Person was granted 7,976 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award. F6 · derivative.expiration_date: On March 15, 2024, the Reporting Person was granted 7,976 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:39 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 781 | $14.20 | $11,090.20 |
DisclosureSEC source: 0001193125-26-111492 · ownership.xml · nonDerivative · entry 5 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,107 F4 · shares: Reflects an aggregate of 781 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:39 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 2,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111492 · ownership.xml · nonDerivative · entry 4 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:39 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111492 · ownership.xml · derivative · entry 6 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,550 Underlying: Common Stock · 3,774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: On March 14, 2025, the Reporting Person was granted 11,324 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award. F5 · derivative.expiration_date: On March 14, 2025, the Reporting Person was granted 11,324 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:39 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 1,449 | $14.20 | $20,575.80 |
DisclosureSEC source: 0001193125-26-111492 · ownership.xml · nonDerivative · entry 3 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,230 F3 · shares: Reflects an aggregate of 1,449 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:39 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 1,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-111492 · ownership.xml · nonDerivative · entry 2 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,679 F2 · shares: On March 14, 2025, the Reporting Person was granted 3,484 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award. Read SEC document |
| March 14, 2026 Filed Mar 17, 2026 23:39 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-111492 · ownership.xml · nonDerivative · entry 1 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:24 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 2,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102238 · ownership.xml · derivative · entry 3 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,197 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: On March 9, 2023, the Reporting Person was granted 6,590 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award. F4 · derivative.expiration_date: On March 9, 2023, the Reporting Person was granted 6,590 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:24 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 639 | $14.96 | $9,559.44 |
DisclosureSEC source: 0001193125-26-102238 · ownership.xml · nonDerivative · entry 2 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,744 F3 · shares: Reflects an aggregate of 639 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:24 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 2,197 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-102238 · ownership.xml · nonDerivative · entry 1 McLeod Ian · CIK 0001447910 · SVP, CAO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock. F2 · balance_after: Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 528 shares purchased on May 14, 2025 and 616 shares purchased on November 14, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.